A phase 2a study of leriglitazone in Rett syndrome (TREE study)
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Leriglitazone (Primary)
- Indications Rett syndrome
- Focus Adverse reactions
- Acronyms TREE
- 14 Mar 2025 New trial record
- 04 Mar 2025 According to Minoryx Therapeutics media release, The results from the TREE study are expected during the first half of 2026 when all patients have concluded 36 weeks of treatment and 4 weeks of follow-up.
- 04 Mar 2025 According to Minoryx Therapeutics media release, company announces that the first patient in the TREE study has been dosed with leriglitazone.